Jennie Chang

1.5k total citations
4 papers, 339 citations indexed

About

Jennie Chang is a scholar working on Surgery, Oncology and Molecular Biology. According to data from OpenAlex, Jennie Chang has authored 4 papers receiving a total of 339 indexed citations (citations by other indexed papers that have themselves been cited), including 2 papers in Surgery, 2 papers in Oncology and 1 paper in Molecular Biology. Recurrent topics in Jennie Chang's work include CAR-T cell therapy research (2 papers), Cancer Immunotherapy and Biomarkers (2 papers) and Lipoproteins and Cardiovascular Health (2 papers). Jennie Chang is often cited by papers focused on CAR-T cell therapy research (2 papers), Cancer Immunotherapy and Biomarkers (2 papers) and Lipoproteins and Cardiovascular Health (2 papers). Jennie Chang collaborates with scholars based in United States. Jennie Chang's co-authors include Lanh Green, Mary Parks, Judy A. Staffa, Patricia Keegan, Meredith K. Chuk, Kun He, Richard Pazdur, Marc R. Theoret, Maitreyee Hazarika and Sirisha L. Mushti and has published in prestigious journals such as The Lancet Oncology, Clinical Cancer Research and Pharmacoepidemiology and Drug Safety.

In The Last Decade

Jennie Chang

4 papers receiving 320 citations

Peers

Jennie Chang
Bas Peters Netherlands
Yufei Feng China
E K Li China
Laurent Kassalow United States
Guangyan Mu China
Matthew M. Riggs United States
Jared Spitz United States
Soamnauth Misir United States
Anees M. Dauki United States
R Bonardi Italy
Bas Peters Netherlands
Jennie Chang
Citations per year, relative to Jennie Chang Jennie Chang (= 1×) peers Bas Peters

Countries citing papers authored by Jennie Chang

Since Specialization
Citations

This map shows the geographic impact of Jennie Chang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennie Chang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennie Chang more than expected).

Fields of papers citing papers by Jennie Chang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennie Chang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennie Chang. The network helps show where Jennie Chang may publish in the future.

Co-authorship network of co-authors of Jennie Chang

This figure shows the co-authorship network connecting the top 25 collaborators of Jennie Chang. A scholar is included among the top collaborators of Jennie Chang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennie Chang. Jennie Chang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

4 of 4 papers shown
1.
Beaver, Julia A., Maitreyee Hazarika, Flora Mulkey, et al.. (2018). Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis. The Lancet Oncology. 19(2). 229–239. 112 indexed citations
2.
Chuk, Meredith K., Jennie Chang, Marc R. Theoret, et al.. (2017). FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma. Clinical Cancer Research. 23(19). 5666–5670. 69 indexed citations
3.
Rowan, Christopher G., Allen Brinker, Parivash Nourjah, et al.. (2009). Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors. Pharmacoepidemiology and Drug Safety. 18(4). 301–309. 41 indexed citations
4.
Chang, Jennie, Judy A. Staffa, Mary Parks, & Lanh Green. (2004). Rhabdomyolysis with HMG‐CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiology and Drug Safety. 13(7). 417–426. 117 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bas Peters Breakdown of academic impact, for papers by Yufei Feng Breakdown of academic impact, for papers by E K Li Breakdown of academic impact, for papers by Laurent Kassalow Breakdown of academic impact, for papers by Guangyan Mu Breakdown of academic impact, for papers by Matthew M. Riggs Breakdown of academic impact, for papers by Jared Spitz Breakdown of academic impact, for papers by Soamnauth Misir Breakdown of academic impact, for papers by Anees M. Dauki Breakdown of academic impact, for papers by R Bonardi
Rankless by CCL
2026